Log in

NASDAQ:ORICPassage Bio Stock Price, Forecast & News

+1.44 (+5.33 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $28.47
50-Day Range N/A
52-Week Range
Now: $28.47
Volume94,600 shs
Average Volume232,238 shs
Market Capitalization$819.71 million
P/E RatioN/A
Dividend YieldN/A
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.94 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORIC



Sales & Book Value

Annual SalesN/A



Market Cap$819.71 million
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive ORIC News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.

Passage Bio (NASDAQ:ORIC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Passage Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Passage Bio.

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for Passage Bio.

How were Passage Bio's earnings last quarter?

Passage Bio (NASDAQ:ORIC) announced its quarterly earnings results on Wednesday, May, 20th. The company reported ($4.46) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $4.20. View Passage Bio's earnings history.

What price target have analysts set for ORIC?

4 brokers have issued 1 year price targets for Passage Bio's shares. Their forecasts range from $35.00 to $45.00. On average, they expect Passage Bio's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 40.5% from the stock's current price. View analysts' price targets for Passage Bio.

Has Passage Bio been receiving favorable news coverage?

Media coverage about ORIC stock has trended very negative on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Passage Bio earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutPassage Bio.

Who are some of Passage Bio's key competitors?

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Beyond Meat (BYND), Crispr Therapeutics (CRSP), Crowdstrike (CRWD), GW Pharmaceuticals PLC- (GWPH), Roku (ROKU), Teladoc Health (TDOC), Trillium Therapeutics (TRIL), Tesla (TSLA), Trade Desk (TTD) and Slack (WORK).

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Jacob M. Chacko M.B.A., M.D., Pres, CEO & Director (Age 41, Pay $672.13k)
  • Mr. Dominic G. Piscitelli C.P.A., M.B.A., CPA, Chief Financial Officer (Age 45, Pay $383.84k)
  • Dr. Pratik S. Multani, Chief Medical Officer (Age 53, Pay $535.16k)
  • Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 61)
  • Dr. Scott W. Lowe, Co-Founder & Member of Scientific Advisory Board

When did Passage Bio IPO?

(ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "ORIC."

When does Passage Bio's quiet period expire?

Passage Bio's quiet period expires on Wednesday, June 3rd. Passage Bio had issued 7,500,000 shares in its initial public offering on April 24th. The total size of the offering was $120,000,000 based on an initial share price of $16.00. During Passage Bio's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Passage Bio?

Shares of ORIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Passage Bio's stock price today?

One share of ORIC stock can currently be purchased for approximately $28.47.

How big of a company is Passage Bio?

Passage Bio has a market capitalization of $819.71 million.

What is Passage Bio's official website?

The official website for Passage Bio is www.oricpharma.com.

How can I contact Passage Bio?

Passage Bio's mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-388-5600 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.